US4259325A - 1,3-Dibenzoic acid esters of 17α-ethynyl-7α-methyl-1,3,5(10)-estratriene-1,3,17β-triol - Google Patents

1,3-Dibenzoic acid esters of 17α-ethynyl-7α-methyl-1,3,5(10)-estratriene-1,3,17β-triol Download PDF

Info

Publication number
US4259325A
US4259325A US06028744 US2874479A US4259325A US 4259325 A US4259325 A US 4259325A US 06028744 US06028744 US 06028744 US 2874479 A US2874479 A US 2874479A US 4259325 A US4259325 A US 4259325A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
methyl
ethynyl
17α
17β
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06028744
Inventor
Klaus Prezewowsky
Hermann Steinbeck
Rudolf Wiechert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0081Substituted in position 17 alfa and 17 beta
    • C07J1/0088Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096Alkynyl derivatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/841Contraceptive
    • Y10S514/843Female mammal
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/874Estrogenic agent, noncontraceptive

Abstract

1,3-Dibenzoic acid esters of 17α-ethynyl-7α-methyl-1,3,5(10)-estratriene-1,3,17β-triol possess strong estrogenic and ovulation-inhibiting activities. As compared to the corresponding diacetic acid ester, these dibenzoic acid esters remain stable over 2-7 months even in the desired, low dosage at a thermal load of up to 60° C.

Description

BACKGROUND OF THE INVENTION

The present invention relates to highly active and stable esters of 17α-ethynyl-7α-methyl-1,3,5(10)-estratriene-1,3,17β-triol, to processes for the preparation thereof and to pharmaceutical compositions containing the same.

German Pat. No. 1,593,509 discloses 1-hydroxy-7α-methylestradiol derivatives of the general formula ##STR1## wherein R1 and R2, which can be the same or different, are hydrogen, lower alkyl, a saturated oxygen-heterocyclic residue, or a physiologically acceptable acid residue, and

R3 is hydrogen or saturated or unsaturated lower alkyl.

These compounds possess valuable therapeutic properties. They are distinguished, in particular, by strong estrogenic and ovulation-inhibiting activities. A preferred compound of the German patent is 17α-ethynyl-1,3-diacetoxy-7α-methyl-1,3,5(10)estratrien-17.beta.-ol (I). During clinical testing also, it proved to be a very strong estrogen for its effectiveness on the endometrium. Compared to 17α-ethynylestradiol, compound I has an activity which is about 10 times higher.

With such highly effective active agents, correspondingly low doses only need be used in preparations. Accordingly, and unfortunately, especially high stabilities are required of the active agents. It has now been found that compound I, in the desired, low dosage in which it is used in a preparation, i.e., 0.001-0.05 mg, is unstable during exertion of a dry temperature load of up to 60° C. over a period of 2-7 months.

Consequently, it is desired to have a highly effective such agent which also has high stability, e.g., storage stability.

SUMMARY OF THE INVENTION

Accordingly, it is an object of the invention to provide estrogenically highly active compounds which also possess high stability.

Upon further study of the specification and appended claims, further objects and advantages of this invention will become apparent to those skilled in the art.

These objects have been attained by providing 1,3-dibenzoic acid esters of 17α-ethynyl-7α-methyl-1,3,5(10)-estratrien-1,3,17β-triol, especially 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl-1,3,5(10)-estratrien-17β-ol.

DETAILED DISCUSSION

Surprisingly, these 1,3-dibenzoic acid esters remain stable under the same thermal load mentioned above with regard to compound I. Furthermore, the benzoic acid esters of this invention have approximately the same advantageous activity as the 1,3-diacetate (I). They are not described in German Pat. No. 1,593,509.

Suitable benzoic acid esters of this invention include the esters of unsubstituted benzoic acid as well as the equivalent esters of benzoic acid having a substituted phenyl nucleus. Suitable such equivalent substituents include chlorine, methyl, hydroxy, amino and methoxy. More generically, other equivalent substituents include bromine, iodine, ethyl and ethoxy. Preferably, one or two of such substituents are present. The unsubstituted 1,3-dibenzoic acid ester is especially preferred.

The preparation of the novel dibenzoic acid esters can be effected according to methods known per se. Thus, a starting material of 17α-ethynyl-7α-methyl-1,3,5(10)-estratrien1,3,17β-triol, described in German Pat. No. 1,593,509 can be conventionally esterified at its free hydroxy groups in the 1- and 3-positions by the desired benzoic acid or a reactive derivative thereof. Preferred such reactive derivatives are the anhydrides and halogenides, especially the chloride. To avoid a simultaneous esterification of the tertiary 17-hydroxy group, the esterification is preferably conducted in the presence of a base, such as, for example, pyridine, at room temperature.

The novel dibenzoic acid esters possess strong estrogenic and ovulation-inhibiting activities in mammals, including humans. They can be conventionally formulated with one or more pharmaceutical vehicles or diluents, optionally with the addition of progestogens, into stable preparations, e.g., tablets, dragees, capsules, solutions, ointments, etc. The effective agent concentration in the pharmaceutical compositions is dependent on the form of application and the field of use. Thus, for example, capsules or tablets for the treatment of gynecological disturbances may contain 0.001-0.05 mg of active ingredient; oily solutions for intramuscular injection may contain, per milliliter, about 0.01-0.1 mg of active ingredient; and vaginal ointments may contain about 0.1-10 mg per 100 ml of ointment.

For female contraceptives, the estrogens of this invention are utilized in combination with conventional progestogens. Tablets or dragees for daily ingestion of one tablet or of one dragee contain preferably 0.003-0.05 mg of the estrogen of this ivention and 0.05-0.5 mg of a progestogen.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the following examples, all temperatures are set forth uncorrected in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight.

EXAMPLE 1

A solution of 2.4 g. of 17α-ethynyl-7α-methyl1,3,5(10)-estratriene-1,3,17β-triol (German Pat. No. 1,593,509) in 28 ml. of pyridine is combined under ice cooling and a protective gas dropwise with 5 ml. of benzoyl chloride and agitated for 40 minutes at 0° C. The batch is thereafter introduced into ice water/sodium chloride, and the oily crude product is obtained as the remainder of a decanting step; this crude product is dissolved in ether. The ether solution is washed with water, dried, and worked up. The crude product is purified by chromatography and recrystallized from cyclohexane, thus obtaining 2.7 g of 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl-1,3,5(10)-estratrien-17β-ol, m.p. 109°-110° C. (under decomposition).

EXAMPLE 2

0.003 g. of 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl1,3,5(10)-estratrien-17.beta.-ol and 209.997 g. of lactose are mixed homogeneously, and respectively 210 mg. of this mixture is filled into hard-gelatin separable capsules of size No. 3.

EXAMPLE 3

0.010 g. of 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl1,3,5(10)-estratrien-17.beta.-ol and 209.990 g. of lactose are mixed homogeneously, and respectively 210 mg. of this mixture is filled into hard-gelatin separable capsules of size No. 3.

EXAMPLE 4

Tablets can be prepared in the usual way from the following ingredients:

______________________________________ 0.010 mg.   17 α-ethynyl-1,3-dibenzoyloxy-7α-methyl-   1,3,5(10)-estratrien-17β-ol 0.100 mg.   17 α-ethynyl-17β-hydroxy-18-methyl-4-estren-3-one   (Levonorgestrel)55.290 mg.   lactose24.000 mg.   microcrystalline cellulose 0.600 mg.   magnesium stearate80.000 mg.   total weight of tablet______________________________________
EXAMPLE 5

Composition of another tablet:

______________________________________ 0.010 mg. 17 α -ethynyl-1,3-dibenzoyloxy-7α-methyl-      1,3,5(10)-estratrien-17β-ol 0.075 mg. 17 α-ethynyl-17β-hydroxy-18-methyl-4,15-      estradien-3-one55.315 mg. mannitol24.000 mg. microcrystalline cellulose 0.600 mg. magnesium stearate80.000 mg. total weight of tablet______________________________________
EXAMPLE 6

Comparative stability tests on 17α-ethynyl-1,3-diacetoxy-7α-methyl-1,3,5(10)-estratrien-17.beta.-ol (I) and 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl-1,3,5(10)-estratrien-17β-ol (II).

Preparation of Powder Mixtures

A: The active agent is dissolved in methylene chloride and applied to lactose, whereafter the methylene chloride is evaporated.

B: Micronized active agent is triturated with lactose.

Active agent concentrations: 1%; 0.01%; 0.003%.

Storage in brown glass jars at room temperature (Rt) (22° C.), at 40° C.; 50° C.; and 60° C.

Results of the potency determination of diacetate I and dibenzoate II (see table).

The potency percentage values by weight listed in the Table were determined by quantitative thin layer chromatography.

                                  TABLE__________________________________________________________________________    2 Months       7 Months   Rt  40° C.           50° C.               60° C.                   Rt  40° C.                           50° C.                               60° C.__________________________________________________________________________Preparation ADiacetate I1%      94% 94% 94% 94% 95% 95% 95% 92%0.01%   100%       90% 87% 48% 95% 83% 55% 0%0.003%  99% 98% 74% 34% 96% 55% 0%  0%Dibenzoate II1%      95% 98% 104%               100%                   104%                       105%                           104%                               96%0.01%   95% 104%           95% 98% 102%                       100%                           95% 105%0.003%  97% 105%           104%               96% 104%                       105%                           95% 89%Preparation BDiacetate I1%      98% 96% 102%               104%                   98% 96% 96% 94%0.01%   100%       84% 73% 70% 100%                       77% 50% 46%0.003%  99% 75% 60% 29% 92% 68% 23% 0%Dibenzoate II1%      99% 102%           101%               105%                   97% 100%                           103%                               104%0.01%   105%       102%           99% 98% 103%                       101%                           102%                               95%0.003%  105%       103%           102%               100%                   99% 96% 95% 88%__________________________________________________________________________

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims (12)

What is claimed is:
1. The 1,3-dibenzoic acid ester of 17α-ethynyl-7α-methyl-1,3,5(10)--estratrien-1,3,17β-triol, and the corresponding esters wherein the phenyl ring of the benzoic acid residue is substituted by chlorine, bromine, iodine, methyl, ethyl, hydroxy, amino, methoxy or ethoxy.
2. 17α-Ethynyl-1,3-dibenzoyloxy-7α-methyl-1,3,5(10)-estratrien-17β-ol.
3. A pharmaceutical composition comprising an estrogenically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
4. The composition of claim 3, wherein the active compound is 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl-1,3,5(10)-estratrien-17β-ol.
5. A method of achieving estrogenic effects in a mammal which comprises administering to the mammal an estrogenically effective amount of a compound of claim 1.
6. The method of claim 5 wherein the compound administered is 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl-1,3,5(10)-estratrien-17β-ol.
7. A method of inhibiting ovulation in a mammal which comprises administering to the mammal an amount of a compound of claim 1 effective to inhibit ovulation.
8. The method of claim 7 wherein the compound administered is 17α-ethynyl-1,3-dibenzoyloxy-7α-methyl-1,3,5(10)-estratrien-17β-ol.
9. The composition of claim 3 which further comprises a progestationally effective amount of a protestogen.
10. The composition of claim 4 which further comprises a progestationally effective amount of a progestogen.
11. The composition of claim 3, wherein the amount of estrogenic ingredient is 0.01-0.003 wt.%.
12. The composition of claim 4, wherein the amount of estrogenic ingredient is 0.01-0.003 wt.%.
US06028744 1978-04-21 1979-04-10 1,3-Dibenzoic acid esters of 17α-ethynyl-7α-methyl-1,3,5(10)-estratriene-1,3,17β-triol Expired - Lifetime US4259325A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE2818164 1978-04-21
DE19782818164 DE2818164A1 (en) 1978-04-21 1978-04-21 1,3-dibenzoesaeureester of 17alpha- ethynyl-7 alpha -methyl-1,3,5 (10) -oestratrien- 1,3,17 beta triol, processes for their preparation and compositions containing them, pharmaceutical

Publications (1)

Publication Number Publication Date
US4259325A true US4259325A (en) 1981-03-31

Family

ID=6037985

Family Applications (1)

Application Number Title Priority Date Filing Date
US06028744 Expired - Lifetime US4259325A (en) 1978-04-21 1979-04-10 1,3-Dibenzoic acid esters of 17α-ethynyl-7α-methyl-1,3,5(10)-estratriene-1,3,17β-triol

Country Status (7)

Country Link
US (1) US4259325A (en)
EP (1) EP0004898B1 (en)
JP (1) JPS54141756A (en)
CA (1) CA1123426A (en)
DE (1) DE2818164A1 (en)
DK (1) DK153279A (en)
ES (1) ES479691A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
US6225298B1 (en) 1994-11-22 2001-05-01 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
US20030207855A1 (en) * 2000-03-10 2003-11-06 Hill Edward N. Novel estrogenic compounds
US20040198670A1 (en) * 2003-04-04 2004-10-07 Hill Edward N. Novel estrogenic compounds
US20040259851A1 (en) * 2003-04-11 2004-12-23 Leonard Thomas W. Methods of administering estrogens and progestins
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
US20070142307A1 (en) * 2000-03-10 2007-06-21 Barr Laboratories, Inc. Novel estrogenic compounds
US20100234330A1 (en) * 2003-07-23 2010-09-16 Hill Edward N Novel Estrogenic Compounds

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3022337C2 (en) * 1980-06-11 1989-10-19 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De
US4757062A (en) * 1985-11-01 1988-07-12 E. I. Du Pont De Nemours And Company Substituted benzoate ester prodrugs of estrogens
JP5357108B2 (en) * 2010-06-29 2013-12-04 大陽日酸株式会社 Burner combustion method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024256A (en) * 1961-02-20 1962-03-06 Searle & Co 16-substituted 1, 3-diacyloxyestra-1, 3, 5(10)-trien-17-ones
US3310470A (en) * 1963-11-09 1967-03-21 Schering Ag Androstane-1alpha, 3alpha, 17beta-triol and fatty acid esters thereof
US3574197A (en) * 1968-07-09 1971-04-06 Schering Ag Process of producing 1-hydroxy-7alpha-methyl-estradiol derivatives
US3951959A (en) * 1973-07-13 1976-04-20 Schering Aktiengesellschaft 1,3-Oxygenated 8α-estratrienes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861086A (en) * 1957-12-27 1958-11-18 Searle & Co 17-oxygenated estra-1, 3, 5(10)-triene-1, 3-diols, and the corresponding esters and ethers
FR1580268A (en) * 1968-06-10 1969-09-05

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024256A (en) * 1961-02-20 1962-03-06 Searle & Co 16-substituted 1, 3-diacyloxyestra-1, 3, 5(10)-trien-17-ones
US3310470A (en) * 1963-11-09 1967-03-21 Schering Ag Androstane-1alpha, 3alpha, 17beta-triol and fatty acid esters thereof
US3574197A (en) * 1968-07-09 1971-04-06 Schering Ag Process of producing 1-hydroxy-7alpha-methyl-estradiol derivatives
US3951959A (en) * 1973-07-13 1976-04-20 Schering Aktiengesellschaft 1,3-Oxygenated 8α-estratrienes

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
US6225298B1 (en) 1994-11-22 2001-05-01 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
US20070142307A1 (en) * 2000-03-10 2007-06-21 Barr Laboratories, Inc. Novel estrogenic compounds
US20030207855A1 (en) * 2000-03-10 2003-11-06 Hill Edward N. Novel estrogenic compounds
US7749989B2 (en) 2000-03-10 2010-07-06 Duramed Pharmaceuticals, Inc. Estrogenic compounds, methods of using and methods of administering the same
US20090105198A1 (en) * 2000-03-10 2009-04-23 Duramed Pharmaceuticals, Inc. Novel estrogenic compounds
US6844334B2 (en) 2000-03-10 2005-01-18 Endeavor Pharmaceuticals (3) and (6) substitued estrogenic compounds
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7459445B2 (en) 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7179799B2 (en) 2000-03-10 2007-02-20 Barr Laboratories, Inc. (3) and (6) substituted estrogenic compounds
US8227454B2 (en) 2000-03-10 2012-07-24 Duramed Pharmaceuticals, Inc. Estrogenic compounds, pharmaceutical compositions and formulations comprising the same
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
US20040198670A1 (en) * 2003-04-04 2004-10-07 Hill Edward N. Novel estrogenic compounds
US20040259851A1 (en) * 2003-04-11 2004-12-23 Leonard Thomas W. Methods of administering estrogens and progestins
US20100234330A1 (en) * 2003-07-23 2010-09-16 Hill Edward N Novel Estrogenic Compounds
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use

Also Published As

Publication number Publication date Type
DK153279A (en) 1979-10-22 application
EP0004898A1 (en) 1979-10-31 application
DE2818164A1 (en) 1979-10-31 application
ES479691A1 (en) 1979-08-01 application
CA1123426A1 (en) grant
CA1123426A (en) 1982-05-11 grant
EP0004898B1 (en) 1982-04-07 grant
JPS54141756A (en) 1979-11-05 application

Similar Documents

Publication Publication Date Title
US3492321A (en) Cyclopropenyl estra, -1,3,5(10)-trienes
Hirschmann et al. Synthesis and structure of steroidal Pregn-4-eno-and 5α-Pregnano [3, 2-c] pyrazoles. A novel class of potent anti-inflammatory steroids
US3166577A (en) 1, 2-dimethyl estrogens and intermediates used in the production thereof
Fishman Synthesis of 2-Methoxyestrogens1
US4022891A (en) Novel 1α,24-dihydroxycholecalciferol compositions, novel precursors thereof, and processes for preparing them
US3984544A (en) Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
Robeson et al. Neovitamin A1
US4212864A (en) Branched chain and cycloaliphatic esters of the androstane and oestrane series and pharmaceutical compositions containing same
Kelly et al. Isolation and characterization of human urinary metabolites of aldosterone. III. Three isomeric tetrahydro metabolites
US2666769A (en) 17-glycolyl-estradiols
US4027019A (en) 3-Oximes of D-17α-ethynyl-19-nortestosterone esters and method
US4738957A (en) Estriol esters
US2590978A (en) Introduction of a double bond adjacent a keto group in ketosteroids
US3946052A (en) 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
US3340279A (en) 7alpha-methyl-steroids of the oestrane series
Welsh The constitution of acetylephedrine and acetyl-ψ-ephedrine
US3591688A (en) Method of preventing ovulation and composition therefor
US4317818A (en) Method of treating prostatic carcinoma
Reed Jr The Preparation of α, α-Dichloro Ketones1
US3381003A (en) 3-keto-13beta-alkyl-17beta-acetyl-gona-4-ene-17alpha-ol compounds and processes of preparing them
US4780461A (en) 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
US3159543A (en) 3-cyclopentyl and cyclopentenyl ethers of estrone and derivatives thereof
Fishman et al. Synthesis of 1, 3, 5 (10)-Estratriene-3, 16β, 17α-triol1
US3198707A (en) 9beta-isomers of estradiol, processes of making the same and their utilization
US2910486A (en) 10-hydroxyestra-1, 4-diene-3, 17-dione and acetate